“We have been commercial since late 2017,” said the company’s CEO, Yan Zhang, in a recent interview.
Initially focusing on oncology, Mission Bio has cast its gaze across precision medicine to cell and gene therapies. “We’re really in this incredible cross-section of oncology and cell and gene therapy,” Zhang said.
The company’s Tapestri platform can simultaneously provide:Genotype and immunophenotype data from a single cell. Detection of copy number variants (CNV).
Mission Bio has raised $110.9 million to date.
Zhang said that the company aims to “help drug developers take precision medicine to the next level.”